Clinical Trials
39 trialsNGS as the First-line Treatment in Advanced Biliary Tract Cancer
National Health Research Institutes, Taiwan
Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma
Yonsei University
KEYNOTE-659
Merck Sharp & Dohme LLC
Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS
Asan Medical Center
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
ChineseAMS
Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer
Yonsei University
Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
Osaka Medical Center for Cancer and Cardiovascular Diseases
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Hallym University Medical Center
Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer
Hallym University Medical Center
Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK
Hokuriku-Kinki Immunochemotherapy Study Group
S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer
Hallym University Medical Center
SOPP
Asan Medical Center
Sorafenib Plus S-1 in Advanced Solid Tumors
National Health Research Institutes, Taiwan
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Japan Breast Cancer Research Network
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
Yonsei University
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer
ChineseAMS
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Gemcitabine and S-1 for Advanced Biliary Tract Cancer
Hallym University Medical Center
TORCH
Seoul National University Hospital
A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer
Yonsei University
Postoperative Chemoradiotherapy With S-1 in Gastric Cancer
Chonnam National University Hospital
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
GEST
Taiho Pharmaceutical Co., Ltd.
Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer
Hallym University Medical Center
Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer
Hallym University Medical Center
TPSHNSCC
Chonnam National University Hospital
Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
Samsung Medical Center
Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
Taiho Pharmaceutical Co., Ltd.
Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer
Japan Clinical Cancer Research Organization
GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
Japan Clinical Cancer Research Organization
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Japan Clinical Cancer Research Organization
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
AstraZeneca
TIROX2
National Cancer Center, Korea
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer
Samsung Medical Center
A Phase â…¡ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
Korea University Anam Hospital